1067198-74-6

Basic information

• Product Name: Icariin derivative
• Synonyms: Icariin derivative;5-hydroxy-3,7-bis(2-hydroxyethoxy)-2-(4-Methoxyphenyl)-8-(3-Methylbut-2-en-1-yl)-4H-chroMen-4-one
• CAS NO: 1067198-74-6
• Molecular Formula: C₂₅H₂₈O₈
• Molecular Weight: 456.48502
• EINECS: -0
• Mol File: 1067198-74-6.mol

Chemical Properties

• Boiling Point: 710.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.34±0.1 g/cm3(Predicted)
• PKA: 6.09±0.40(Predicted)
• CAS DataBase Reference: Icariin derivative(CAS DataBase Reference)
• NIST Chemistry Reference: Icariin derivative(1067198-74-6)
• EPA Substance Registry System: Icariin derivative(1067198-74-6)

Safety Data

• Hazardous Substances Data: 1067198-74-6(Hazardous Substances Data)

Usage

Uses

Used in Sexual Performance Enhancement:
Icariin derivative is used as a sexual performance enhancer for its ability to improve sexual function and combat erectile dysfunction.
Used in Bone Health Promotion:
Icariin derivative is used as a bone health promoter for its potential to support bone health and prevent conditions like osteoporosis.
Used in Neuroprotection:
Icariin derivative is used as a neuroprotective agent for its potential to protect the nervous system and prevent neurodegenerative diseases.
Used in Anti-Inflammatory Applications:
Icariin derivative is used as an anti-inflammatory agent for its potential to reduce inflammation and alleviate inflammatory conditions.
Used in Cardiovascular Protection:
Icariin derivative is used as a cardiovascular protector for its potential to support heart health and prevent cardiovascular diseases.
Used in Anti-Osteoporosis Applications:
Icariin derivative is used as an anti-osteoporosis agent for its potential to strengthen bones and prevent osteoporosis.
Used in Anti-Tumor Activities:
Icariin derivative is used as an anti-tumor agent for its potential to inhibit tumor growth and promote cancer treatment.

Upstream product

• 113558-15-9 icariside II 
• 118525-40-9 icaritin 
• 540-51-2 2-bromoethanol 

Relevant articles and documents

3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats

Pulmonary arterial hypertension (PAH) is a chronic progressive disease which leads to elevated pulmonary arterial pressure and right heart failure. 3,7-Bis(2-hydroxyethyl)icaritin (ICT), an icariin derivatives, was reported to have potent inhibitory activ

Synthesis and cancer cell growth inhibitory activity of icaritin derivatives

Abstract A series of icaritin derivatives bearing carboxylic acid or carboxylic ester groups are synthesized, and their in vitro cytotoxic activity against three cancer cell lines, MCF-7, MDA-MB-435s, and A549, are evaluated by MTT assay. Several derivati

Icaritin (ICT) derivative and preparation method and application thereof

The invention belongs to the field of pharmaceutical chemistry, and particularly relates to an icaritin (ICT) derivative shown as the formula (II), a pharmacologically-allowable salt and preparation method of the ICT derivative, and application of the ICT

Icaritin (ICT) derivative and preparation method and application thereof

The invention belongs to the field of pharmaceutical chemistry, and particularly relates to an icaritin (ICT) derivative shown as the formula (I), a pharmacologically-allowable salt and preparation method of the ICT derivative, and application of the ICT

Herba Epimedii glycoside compound and use thereof

The invention relates to an icariin compound and an application of the icariin compound in preparing medicines for preventing and treating fracture and osteoporosis. Particularly, the invention relates to the compound shown in a general formula (I) in the specification, a stereisomer, a stereomer, a tautomer, oxynitrides, hydrates, solvates, metabolites, and pharmaceutically acceptable salts or prodrugs thereof, wherein the variables are defined in the specification. The invention further relates to use of the compound, the stereisomer, the stereomer, the tautomer, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or salt of prodrugs thereof as medicines, particularly use in preparing medicines for preventing and treating fracture and osteoporosis.

Herba Epimedii derivative and its preparation and use

The invention discloses icaritin derivatives as well as a preparation method and application thereof. The structure of the icaritin derivatives is showed in the formula (1), wherein m is equal to 2 and n is equal to 3 in a compound 1; or m is equal to 3 a

Potent inhibition of human phosphodiesterase-5 by icariin derivatives

Plant extracts traditionally used for male impotence (Tribulus terrestris, Ferula hermonis, Epimedium brevicornum, Cinnamomum cassia), and the individual compounds cinnamaldehyde, ferutinin, and icariin, were screened against phosphodiesterase-5A1 (PDE5A1) activity. Human recombinant PDE5A1 was used as the enzyme source. Only E. brevicornum extract (80% inhibition at 50 μg/mL) and its active principle icariin (1) (IC50 5.9 μM) were active. To improve its inhibitory activity, 1 was subjected to various structural modifications. Thus, 3,7-bis(2-hydroxyethyl)icaritin (5), where both sugars in 1 were replaced with hydroxyethyl residues, potently inhibited PDE5A1 with an IC50 very close to that of sildenafil (IC50 75 vs 74 nM). Thus, 5 was 80 times more potent than 1, and its selectivity versus phosphodiesterase-6 (PDE6) and cyclic adenosine monophosphate-phosphodiesterase (cAMP-PDE) was much higher in comparison with sildenafil. The improved pharmacodynamic profile and lack of cytotoxicity on human fibroblasts make compound 5 a promising candidate for further development.